| pubmed-article:21750558 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1123023 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1556085 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1825590 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C2697648 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C0087113 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:21750558 | lifeskim:mentions | umls-concept:C1707520 | lld:lifeskim |
| pubmed-article:21750558 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21750558 | pubmed:dateCreated | 2011-7-13 | lld:pubmed |
| pubmed-article:21750558 | pubmed:abstractText | The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first-line treatment of metastatic colorectal cancer (mCRC). Treatment-related skin toxicity (ST) was evaluated separately for capecitabine and cetuximab. The present analysis investigates the correlation of capecitabine-attributed ST (Cape-ST) and parameters of treatment efficacy. | lld:pubmed |
| pubmed-article:21750558 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21750558 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21750558 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21750558 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:21750558 | pubmed:issn | 1532-1827 | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:KleinSS | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:StauchMM | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:KappaufHH | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:SchulzeMM | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:Dietzfelbinge... | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:DeckerTT | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:AbenhardtWW | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:MittermüllerJ... | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:HeinemannVV | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:Vehling-Kaise... | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:HaberlCC | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:ZellmannKK | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:OruzioDD | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:HassH GHG | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:MoosmannNN | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:StintzingSS | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:Fischer von... | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:PuchtlerGG | lld:pubmed |
| pubmed-article:21750558 | pubmed:author | pubmed-author:GiessenCC | lld:pubmed |
| pubmed-article:21750558 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21750558 | pubmed:day | 12 | lld:pubmed |
| pubmed-article:21750558 | pubmed:volume | 105 | lld:pubmed |
| pubmed-article:21750558 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21750558 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21750558 | pubmed:pagination | 206-11 | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:meshHeading | pubmed-meshheading:21750558... | lld:pubmed |
| pubmed-article:21750558 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21750558 | pubmed:articleTitle | Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. | lld:pubmed |
| pubmed-article:21750558 | pubmed:affiliation | Medical Department III, University of Munich, Klinikum Muenchen-Grosshadern, Marchioninistrasse 15, D-81377 Munich, Germany. | lld:pubmed |
| pubmed-article:21750558 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21750558 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:21750558 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21750558 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21750558 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
